SD 169

CAS No. 1670-87-7

SD 169( —— )

Catalog No. M20928 CAS No. 1670-87-7

SD 169 is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
50MG 32 In Stock
100MG 47 In Stock
200MG 70 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SD 169
  • Note
    Research use only, not for human use.
  • Brief Description
    SD 169 is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
  • Description
    SD 169 is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
  • In Vitro
    SD-169 significantly reduces p38 and HSP60 expression in T cells of the pancreatic beta islets.SD-169 demonstrates 38-fold potency against p38α MAP kinase (IC50=3.2 nM) than p38β MAP kinase (IC50=122 nM).
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    p38
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1670-87-7
  • Formula Weight
    160.17
  • Molecular Formula
    C9H8N2O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (624.30 mM)
  • SMILES
    NC(=O)c1ccc2[nH]ccc2c1
  • Chemical Name
    1H-Indole-5-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Myers R R Sekiguchi Y Kikuchi S et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration[J]. Experimental Neurology 2003 184(2):0-614.
molnova catalog
related products
  • SSK1

    SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.

  • p38α inhibitor 4

    p38α inhibitor 4 is a selective MAPK p38α inhibitor, which is used to study diabetes, pain and chronic inflammation.

  • SM1-71

    SM1-71 is a potent multi-targeted acrylamide-modified TAK1 inhibitor that inhibits MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2.